Drug offers ‘wonderful’ breakthrough in treatment of asbestos-linked cancer

Andrew Gregory, The Guardian

Researchers have achieved a breakthrough in the treatment of mesothelioma, a challenging cancer linked to asbestos exposure, marking the most substantial advancement in two decades. A new drug, ADI-PEG20, when combined with chemotherapy, has shown remarkable results in a multinational trial, quadrupling three-year survival rates for patients. Led by Queen Mary University of London, the trial involved patients from five countries and demonstrated a significant increase in median overall survival compared to chemotherapy alone. The drug works by depleting arginine levels crucial for tumor growth, addressing a vulnerability discovered after two decades of research. The success of this therapy offers renewed hope for mesothelioma patients and their families, with implications for future treatment standards and improved outcomes. Read the article here.